

LIST OF PUBLICATIONS

A. BOOKS AND MONOGRAPHS

1. A. Del Castillo, A. Eyzaguirre, U. Katz, J. Millones, H. Miranda, L. Palomino, J. Pino.
Anatomía del Sistema Nervioso.
Anatomy of the Nervous System [Spanish].
Cayetano Heredia University Press. 190 pp., 1995.
2. U. Katz.
Impacto de la Vacuna WC/rBS Sobre la Tasa de Incidencia de Colera en una Población Urbano-Marginal de Lima: Vigilancia de Dos Años.
Impact of the WC/rBS vaccine on the cholera incidence rate in a shanty-town population of Lima: Two year surveillance [Spanish].
Thesis to obtain the degree of Medicinae Doctor (M.D.).
Cayetano Heredia University Press. 62 pp., 1997.
3. U. Katz.
Role of the Light Subunit of the Gal-Lectin in the pathogenesis of *Entamoeba histolytica*. Comparison of the Tools used for Recombinant Molecular Expression in *Entamoeba histolytica*.
Thesis to obtain the degree of Philosophiae Doctor (Ph.D.) in Life Sciences.
Weizmann Institute of Science Press. 117 pp., 2003.

B1. ORIGINAL ARTICLES

1. S. Ankri, F. Padilla-Vaca, T. Stolarsky, L. Koole, U. Katz, D. Mirelman.
Antisense inhibition of expression of the light subunit (35 kDa) of the Gal/GalNac lectin complex inhibits *Entamoeba histolytica* virulence.
Mol Microbiol, Vol. 33, pp. 327-37, 1999.
2. D.E. Roth, D.N. Taylor, R.H. Gilman, R. Meza, U. Katz, C. Bautista, L. Cabrera, B. Velapatino, C. Lebron, M. Razuri, J. Watanabe, T. Monath.
Posttreatment follow-up of *Helicobacter pylori* infection using a stool antigen immunoassay.
Clin Diagn Lab Immunol, Vol. 8, pp. 718-23, 2001.
3. U. Katz, S. Ankri, T. Stolarsky, Y. Nuchamowitz, D. Mirelman.
Entamoeba histolytica expressing a dominant negative N-truncated light subunit of its gal-lectin are less virulent.
Mol Biol Cell, Vol. 13, pp. 4256-65, 2002.
4. U. Katz, R. Bracha, Y. Nuchamowitz, O. Milstein, D. Mirelman.
Comparison between constitutive and inducible plasmid vectors used for gene expression in *Entamoeba histolytica*.
Mol Biochem Parasitol, Vol. 128, pp. 229-33, 2003.
5. G. Soto, C.T. Bautista, D.E. Roth, R.H. Gilman, B. Velapatino, M. Ogura, G. Dailide, M. Razuri, R. Meza, U. Katz, T.P. Monath, D.E. Berg, D.N. Taylor.
Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy.
J Infect Dis, Vol. 188, pp. 1263-75, 2003.
6. S. Bujanover, U. Katz, R. Bracha, D. Mirelman.
A virulence attenuated amoebapore-less mutant of *Entamoeba histolytica* and its interaction with host cells.
Int J Parasitol, Vol. 33, pp. 1655-63, 2003.

7. U. Katz, N. Zilberman, I. Rusinek, E. Schwartz.
משלחת ישראלית במגיפת כולרה בגינאה המשוונית
Israeli Mission to Equatorial Guinea During a Cholera Outbreak [Hebrew].
Harefuah, Vol.144, pp. 306-9, 2005.
8. U. Katz, N. Zilberman, I. Rusinek, E. Schwartz.
Caring for the caregivers.
J Travel Med, Vol. 13, pp. 63-6, 2006.
9. U. Katz, I. Kishner, D. Magalashvili, Y. Shoenfeld, A. Achiron.
Long Term Safety of IVIg Therapy in Multiple Sclerosis: 10 Years Experience.
Autoimmunity, Vol 39, pp. 513-7, 2006.

B2. CASE REPORTS

1. U. Katz.
מחוסר בית עם גוש גדול בדופן בית-החזה
Homeless with a giant cauliflower-like tumor on the chest wall [Hebrew].
Harefuah, Vol.143, pp. 152, 2004.
2. I. Danylesko, U. Katz.
דיונים קליניים בישיבת מתמחים ב-8 בנובמבר 2005
Clinical discussions of the Internal Medicine Residents, Sheba, Tel Hashomer,
November 8th, 2005. [Hebrew].
Harefuah, Vol.145, pp. 607-9, 2006.
3. E. Zimlichman, M. Szyper-Kravitz, U. Katz, Y. Shoenfeld.
Intensive lipid lowering therapy: obvious benefits, possible risks.
Isr Med Assoc J, Vol. 8, pp. 890-1, 2006.

B3. REVIEW ARTICLES

1. Y. Shoenfeld, U. Katz.
IVIg therapy in autoimmunity and related disorders: our experience with a large
cohort of patients.
Autoimmunity, Vol. 38, pp. 123-137, 2005.
2. U. Katz, Y. Shoenfeld.
Review: intravenous immunoglobulin therapy and thromboembolic
complications.
Lupus, Vol. 14, pp. 802-808, 2005.
3. H. Orbach, U. Katz, Y. Sherer, Y. Shoenfeld.
Intravenous Immunoglobulin: Adverse Effects and Safe Administration.
Clin Rev Allergy Immunol, Vol 29, pp. 173-184, 2005.
4. A. Etzioni, Y. Sherer, H. Carp, D. Mimouni, A. Achiron, G. Goddard, U. Katz, Y.
Shoenfeld.
נייר עמדה בנושא טיפול באימונוגלובולינים לתוך הווריד
Indications – Intravenous Immunoglobulins - IVIg [Hebrew].
Harefuah, Vol.144, pp. 799-804, 2005.
5. U. Katz, Y. Molad, J. Ablin, D. Ben-David, D. Paran, M. Gutman, P. Langevitz.
Chronic Idiopathic Granulomatous Mastitis.
Ann N Y Acad Sci, Vol. 1108, pp. 603–608, 2007.
6. Y. Shoenfeld, G. Twig, U. Katz, Y. Sherer.
Autoantibody Explosion in Antiphospholipid Syndrome.
J Autoimmun, Vol. 30, pp. 74-83, 2008.

7. Y. Shoenfeld, B. Gilburd, M. Abu-Shakra, H. Amital, O. Barzilai, Y. Berkun, M. Blank, G. Zandman-Goddard, U. Katz, I. Krause, P. Langevitz, Y. Levy, H. Orbach, V. Pordeus, M. Ram, Y. Sherer, E. Toubi, Y. Tomer.
The mosaic of autoimmunity: genetic factors involved in autoimmune diseases--2008.
Isr Med Assoc J, Vol. 10, pp. 3-7, 2008.
8. Y. Shoenfeld, G. Zandman-Goddard, L. Stojanovich, M. Cutolo, H. Amital, Y. Levy, M. Abu-Shakra, O. Barzilai, Y. Berkun, M. Blank, J.F. de Carvalho, A. Doria, B. Gilburd, U. Katz, I. Krause, P. Langevitz, H. Orbach, V. Pordeus, M. Ram, E. Toubi, Y. Sherer.
The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases--2008.
Isr Med Assoc J, Vol. 10, pp. 8-12, 2008.
9. Y. Shoenfeld, M. Blank, M. Abu-Shakra, H. Amital, O. Barzilai, Y. Berkun, N. Bizzaro, B. Gilburd, G. Zandman-Goddard, U. Katz, I. Krause, P. Langevitz, I.R. Mackay, H. Orbach, M. Ram, Y. Sherer, E. Toubi, M.E. Gershwin.
The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases--2008.
Isr Med Assoc J, Vol. 10, pp. 13-19, 2008.
10. U. Katz, Y. Shoenfeld.
Pulmonary Eosinophilia.
Clin Rev Allergy Immunol, Vol. 34, pp. 367–371, 2008.
11. U. Katz, B. Gilburd, Y. Shoenfeld.
Animal Models of Vasculitides.
Clin Rev Allergy Immunol, Vol. 35, pp. 11–18, 2008.
12. S. Kivity, U. Katz, N. Daniel, U. Nussinovitch, N. Papageorgiou, Y. Shoenfeld.
Evidence for the Use of Intravenous Immunoglobulins-A Review of the Literature.
Clin Rev Allergy Immunol, Vol. 38, pp. 201-269, 2010.
13. U. Katz, G. Zandman-Goddard.
Drug-induced lupus: An update.
Autoimmun Rev, Vol. 10, pp. 46-50, 2010.
14. U. Katz, Y. Shoenfeld, G. Zandman-Goddard.
Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off-Label use in Autoimmune Diseases.
Curr Pharm Des, 2011, Vol. 17, pp. 3166-3175.
15. U. Katz, Y. Shoenfeld, V. Zakin, Y. Sherer, S. Sukenik.
Scientific Evidence of the Therapeutic Effects of Dead Sea Treatments: A Systematic Review.
Semin Arthritis Rheum, 2012, Vol 42, pp. 186-200.

C. CHAPTERS IN BOOKS

1. U. Katz, R.H. Gilman.
Tratamiento de la infección por *Helicobacter pylori* en los países en vías de desarrollo.
Treatment of *Helicobacter pylori* infection in developing countries [Spanish].
In: J.M. Pajares-Garcia, P. Correa, G.I. Perez-Perez, eds.
Infección por *Helicobacter pylori* en lesiones gastroduodenales. La segunda década.
Helicobacter pylori infection in gastroduodenal lesions. The second decade [Spanish].
Prous Science, pp. 253-62, 1998.

2. U. Katz.
טיפול באימונוגלובולינים לתוך הווריד במחלות אוטואימוניות
Intravenous Immunoglobulin Treatment in Autoimmune Diseases [Hebrew].
In: Y Shoenfeld, ed.
מחלות אוטואימוניות- פרקים נבחרים
Autoimmune Diseases – Selected Chapters [Hebrew].
Aurora Medical Publications, 2006.
3. M. Blank, U. Katz, Y. Shoenfeld.
Modelos Experimentales de LES: Mecanismos Moleculares Involucrados en la Enfermedad.
Experimental Models of SLE: Molecular Mechanisms Involved in the Disease [Spanish].
In: M.A. Khamashta, M. Vilardell, eds.
Lupus Eritematoso Sistémico.
Systemic Lupus Erythematosus [Spanish].
Caduceo Multimedia S.L., pp. 81-92, 2009.

D1. PAPERS PRESENTED AT SCIENTIFIC MEETINGS PUBLISHED AS PROCEEDINGS

1. D. Mirelman, S. Ankri, U. Katz, F. Padilla-Vaca, R. Bracha.
Pathogenesis of *Entamoeba histolytica* depends on the concerted action of numerous virulence factors.
Arch Med Res, Vol. 31, pp. S214-5, 2000.
2. A. Leroy, T. Lauwaet, M. Oliveira, G. De Bruyne, R. Bracha, S. Ankri, U. Katz, D. Mirelman, M. Mareel.
Disturbance of tight junctions by *Entamoeba histolytica*: resistant vertebrate cell types and incompetent trophozoites.
Arch Med Res, Vol. 31, pp. S218-20, 2000.
3. S. Ankri, U. Katz, T. Stolarsky, D. Mirelman.
Does the light subunit of the Gal/GalNAc specific lectin have a role in the virulence of *Entamoeba histolytica*?
Arch Med Res, Vol. 31, pp. S239-41, 2000.
4. U. Katz, A. Achiron, Y. Sherer, Y. Shoenfeld.
Safety of Intravenous Immunoglobulin (IVIg) therapy.
Autoimmun Rev, Vol 6, pp. 257-9, 2007.
5. J. Schachter*, U. Katz*, A. Marer, D. Barak, L. Ziegel Ben David, J. Nusbacher, Y. Shoenfeld. (*The first two authors contributed equally to the paper).
Efficacy and Safety of Intravenous Immunoglobulin (IVIg) in Patients with Metastatic Melanoma.
5th International Congress on Autoimmunity.
Sorrento, 2006.
Ann N Y Acad Sci, Vol 1110, pp. 305-314, 2007.

D2. ABSTRACTS PRESENTED AT SCIENTIFIC MEETINGS

1. S. Ankri, U. Katz, T. Stolarsky, D. Mirelman.
Use of a Dominant Negative Approach to Identify the Role of the Light Subunit of the Gal/GalNAc Lectin Complex of *Entamoeba histolytica*.
Annual Meeting of the Israeli Society of Microbiology, Haifa, 2000.
2. U. Katz, S. Ankri, T. Stolarsky, Y. Nuchamowitz, D. Mirelman.
Removal of the N-Terminal Part of the Light Subunit of the Gal/GalNAc Lectin of *Entamoeba histolytica* Reduces Amoebic Virulence.
Annual Meeting of the Israeli Society of Microbiology, Beer Sheva; 2001.

3. U. Katz, S. Ankri, T. Stolarsky, Y. Nuchamowitz, D. Mirelman.
Overexpression of a N-terminal truncated light subunit of the Gal/GalNAc lectin of *Entamoeba histolytica* reduces amoebic virulence.
The 3rd Congress of the Federation of Israel Societies for Experimental Biology – FISEB 2002, Eilat, 2002.
4. U. Katz, R. Bracha, Y. Nuchamowitz, O. Milstein, D. Mirelman.
Comparison Between Constitutive and Inducible Plasmid Vectors Used for Gene Expression in *Entamoeba histolytica*.
EMBO Workshop on Pathogenesis of Amoebiasis: From Genomics to Disease, Paris, 2003.
5. J. Schachter, U. Katz, A. Mahrer, D. Barak, L.Z. Ben-David, J. Nusbacher, Y. Shoenfeld.
Efficacy and safety of intravenous immunoglobulin (IVIg) in patients with metastatic melanoma.
Annual Meeting of the Israel Association of Allergy and Clinical Immunology, Tzfat, 2007.

E. OTHER PUBLICATIONS

1. U. Katz, E. Schwartz.
Letter to the Editor: Reply.
J Travel Med, Vol. 13, pp. 385, 2006.
2. Editor of the special issue of *Autoimmun Rev* including the proceedings of the Clinical Immunology School on Systemic Autoimmune Diseases, Santa Fe, New Mexico, March 2006.
Autoimmun Rev, Vol. 6, 2007.